Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Deciphera Pharmaceuticals, Inc.    DCPH

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/23/2020 10/26/2020 10/27/2020 10/28/2020 10/29/2020 Date
64.06(c) 62.73(c) 61(c) 58.11(c) 58.97(c) Last
243 405 347 234 317 215 225 295 248 706 Volume
+0.90% -2.08% -2.76% -4.74% +1.48% Change
More quotes
Financials (USD)
Sales 2020 23,3 M - -
Net income 2020 -289 M - -
Net cash position 2020 286 M - -
P/E ratio 2020 -11,2x
Yield 2020 -
Sales 2021 98,6 M - -
Net income 2021 -276 M - -
Net cash position 2021 230 M - -
P/E ratio 2021 -12,2x
Yield 2021 -
Capitalization 3 325 M 3 325 M -
EV / Sales 2020 130x
EV / Sales 2021 31,4x
Nbr of Employees 257
Free-Float 70,5%
More Financials
Company
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal... 
More about the company
Notations Surperformance© of Deciphera Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about DECIPHERA PHARMACEUTICALS, INC.
09:50aDECIPHERA PHARMACEUTICALS : To Announce Third Quarter 2020 Financial Results and..
AQ
10/28DECIPHERA PHARMACEUTICALS, INC. : to Announce Third Quarter 2020 Financial Resul..
BU
10/07Brazil's economic priority is jobs, not fiscal discipline
RE
10/06Venezuela sends two more of its own oil tankers to deliver exports- data
RE
10/06Venezuela sends two more of its own oil tankers to deliver exports - data
RE
10/01Venezuela's PDVSA to install ship-to-ship hub away from shore -sources
RE
09/28Tankers carrying Iranian fuel begin entering Venezuelan waters -data
RE
09/23EXCLUSIVE : PDVSA's customers schedule last oil cargoes amid U.S.-imposed wind-d..
RE
09/23Brazil's steep rate curve should pose no threat to government funding
RE
09/19Court unfreezes accounts of Mexican firm sanctioned by U.S.
RE
09/18DECIPHERA PHARMACEUTICALS : Presents Data from Rebastinib, Its TIE2 Inhibitor Pr..
AQ
09/18DECIPHERA PHARMACEUTICALS : Presents Data from QINLOCK™ (Ripretinib) Progr..
BU
09/17Latin American nations seek more time to join WHO vaccine plan
RE
09/17DECIPHERA PHARMACEUTICALS : Presents Data from Rebastinib, its TIE2 Inhibitor Pr..
BU
09/06Feature-Amid theft and accusations of sabotage, Haiti struggles to turn on th..
RE
More news
News in other languages on DECIPHERA PHARMACEUTICALS, INC.

- No features available -

More news
Chart DECIPHERA PHARMACEUTICALS, INC.
Duration : Period :
Deciphera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DECIPHERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 72,80 $
Last Close Price 58,97 $
Spread / Highest target 54,3%
Spread / Average Target 23,5%
Spread / Lowest Target -11,8%
EPS Revisions
Managers
NameTitle
Steven L. Hoerter President, Chief Executive Officer & Director
James A. Bristol Chairman
Thomas P. Kelly Chief Financial Officer
Daniel L. Flynn Chief Scientific Officer & Executive VP
Stephen B. Ruddy Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
DECIPHERA PHARMACEUTICALS, INC.-5.25%3 276
GILEAD SCIENCES, INC.-9.93%73 619
REGENERON PHARMACEUTICALS48.02%59 670
VERTEX PHARMACEUTICALS-5.45%54 266
WUXI APPTEC CO., LTD.71.35%39 595
BEIGENE, LTD.80.68%27 119